NCT06094777View on ClinicalTrials.gov

A Study of HY-0102 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

HY-0102

Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai YingLi Pharmaceutical Co. Ltd.

INDUSTRY